GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Capex-to-Revenue

Sandoz Group AG (Sandoz Group AG) Capex-to-Revenue : 0.06 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sandoz Group AG's Capital Expenditure for the three months ended in Dec. 2023 was $-625.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $9,979.00 Mil.

Hence, Sandoz Group AG's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.06.

Sandoz Group AG Capex-to-Revenue Historical Data

The historical data trend for Sandoz Group AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Capex-to-Revenue Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Capex-to-Revenue
0.05 0.06

Sandoz Group AG Quarterly Data
Dec22 Dec23
Capex-to-Revenue 0.05 0.06

Competitive Comparison of Sandoz Group AG's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Capex-to-Revenue falls into.


Sandoz Group AG Capex-to-Revenue Calculation

Sandoz Group AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-625) / 9979
=0.06

Sandoz Group AG's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-625) / 9979
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG  (OTCPK:SDZNY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Sandoz Group AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Capex-to-Revenue
Comparable Companies
XSWX:SFZN XSWX:PPGN ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 HKSE:03692 NBIX NSE:DIVISLAB BOM:500124 VTRS SZSE:000963 XPAR:IPN SHSE:600085 XTAE:TEVA SHSE:600196
Traded in Other Exchanges
SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024